Advertisement
UK markets closed
  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     
  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     
  • AIM

    745.67
    +0.38 (+0.05%)
     
  • GBP/EUR

    1.1607
    -0.0076 (-0.65%)
     
  • GBP/USD

    1.2370
    -0.0068 (-0.55%)
     
  • Bitcoin GBP

    51,323.63
    -30.84 (-0.06%)
     
  • CMC Crypto 200

    1,368.41
    +55.79 (+4.25%)
     
  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     
  • DOW

    37,986.40
    +211.02 (+0.56%)
     
  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     
  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     
  • DAX

    17,737.36
    -100.04 (-0.56%)
     
  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     

BUZZ-Top of the Street: ABF, Dassault Aviation, Faurecia, Lundbeck

A round-up of notable broker activity this morning from Europe's top-ranked* analysts:

** 5-star ranked Jefferies's analyst James Grzinic upgrades Associated British Foods Plc (LSE: ABF.L - news) to "buy"; it recognises continued strength in sugar and a turn in Primark margins from 17/18

** Dassault Aviation SA (LSE: 0IAX.L - news) : Credit Suisse (IOB: 0QP5.IL - news) raises to "outperform"; broker sees burgeoning recovery or at least end of deterioration in bizjet market, adding that the planned tax reform in the US would amplify this movement; it also says Rafale success story may continue: "After three export orders booked in two years, more may be coming in the not too distant future, possibly even in H2"

** Faurecia SA: Alphavalue raises to "add" saying that the reported Q1 revenue growth of more than 9 percent was a surprise; broker raises revenue and profit projections for the next few years

ADVERTISEMENT

INITIATIONS:

** H Lundbeck A/S: In a note entitled "Margin recovery story is no longer enough", Kepler Cheuvreux starts coverage with "reduce" saying that Lundbeck’s 130% share price rise over the last two years was driven by an operating margin recovery; broker sees risks from rising US dependence and the greater focus on governmental drug spending; it adds that late-stage pipeline is quite bare

(*Analyst rankings from Thomson Reuters StarMine. Scale is from 1-star to 5-star with 5 being best. Analysts ranked on earnings accuracy as well as relative performance of recommendations over trailing 12-month & 24-month periods)